Stock Events

Stock Events

Filana Therapeutics 

€1.44
345
-€0.06-4.05% Thursday 06:04

Statistics

Day High
1.44
Day Low
1.44
52W High
3.9
52W Low
1.03
Volume
-
Avg. Volume
-
Mkt Cap
69.76M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 12
€4.01
Dec 10
€1.52
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.92
-0.69
-0.45
-0.22
Expected EPS
-0.23
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-130.65MNet Income

Analyst Ratings

$6.07Average Price Target
The highest estimate is 6.07.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PX91.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a leading competitor in the Alzheimer's treatment market, directly competing with Cassava's simufilam.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has developed donanemab, an Alzheimer's disease treatment, competing in the same space as Cassava Sciences.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a history of developing treatments for neurological disorders, including Alzheimer's, making it a competitor.
AC Immune SA
ACIU
Mkt Cap340.03M
AC Immune SA focuses on developing treatments for neurodegenerative diseases, including Alzheimer's, directly competing with Cassava.
Annovis Bio
ANVS
Mkt Cap48.93M
Annovis Bio operates in the Alzheimer's and Parkinson's disease space, making it a competitor to Cassava Sciences.
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Anavex Life Sciences Corp. is working on treatments for Alzheimer's disease, competing in the same market as Cassava.
Athira Pharma Inc
ATHA
Mkt Cap16.39M
Athira Pharma focuses on regenerative therapies for Alzheimer's, positioning it as a competitor to Cassava Sciences.

About

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Show more...
CEO
Mr. Richard Jon Barry
Employees
30
Country
US
ISIN
US14817C1071
WKN
000A2PGL8

Listings

MX
MX
FLNA.MX
XNAS
US
SAVA
F
DE
PX91.F
BOATS
BOATS
SAVA.BOATS

0 Comments

Share your thoughts

FAQ

What is Filana Therapeutics stock price today?▼
The current price of PX91.F is €1.44 EUR — it has decreased by -4.05% in the past 24 hours. Watch Filana Therapeutics stock price performance more closely on the chart.
What is Filana Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Filana Therapeutics stocks are traded under the ticker PX91.F.
Is Filana Therapeutics stock price growing?▼
PX91.F stock has fallen by -4.37% compared to the previous week, the month change is a -25.41% fall, over the last year Filana Therapeutics has showed a +24.48% increase.
What is Filana Therapeutics market cap?▼
Today Filana Therapeutics has the market capitalization of 69.76M
When is the next Filana Therapeutics earnings date?▼
Filana Therapeutics is going to release the next earnings report on May 06, 2026.
What were Filana Therapeutics earnings last quarter?▼
PX91.F earnings for the last quarter are -0.23 EUR per share, whereas the estimation was -0.26 EUR resulting in a +13.33% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Filana Therapeutics revenue for the last year?▼
Filana Therapeutics revenue for the last year amounts to 0 EUR.
What is Filana Therapeutics net income for the last year?▼
PX91.F net income for the last year is -130.65M EUR.
Does Filana Therapeutics pay dividends?▼
Yes, PX91.F dividends are paid en. The last dividend per share was 4.01 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Filana Therapeutics have?▼
As of April 03, 2026, the company has 30 employees.
In which sector is Filana Therapeutics located?▼
Filana Therapeutics operates in the Health Care sector.
When did Filana Therapeutics complete a stock split?▼
The last stock split for Filana Therapeutics was on December 21, 2023 with a ratio of 14:10.
Where is Filana Therapeutics headquartered?▼
Filana Therapeutics is headquartered in Austin, US.